Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 2 of 4: Calculated dose-response metrics. - Dataset (ID:20269)

Filter results: >>>>
Cell Clinical Subtype Transcriptional Subtype Small Molecule Antibody Perturbagen Target Perturbagen Class Biological Replicate ID Conc Unit GR50 GEC50 GRmax GRinf GR Hill Coefficient GR_AOC GR r2 Nominal Division Rate
MDA-MB-415
HR+
Luminal
PD184352
MEK
MAPK
12333.155
uM
inf
inf
0.7011 0.7011 0.0000 0.0780
0.5724
0.5790
MDA-MB-415
HR+
Luminal
PD184352
MEK
MAPK
12333.155
uM
inf
inf
0.7011 0.7011 0.0000 0.0780
0.5724
0.5790
MDA-MB-415
HR+
Luminal
Pemetrexed
TYMS/DHFR/GARFT
TYMS
7510.094
uM
inf
inf
1.0500 1.0500 0.0000 -0.0419
-8.1247
0.8152
MDA-MB-415
HR+
Luminal
Pemetrexed
TYMS/DHFR/GARFT
TYMS
7512.095
uM
inf
inf
0.8257 0.8257 0.0000 0.0736
0.0000
0.8452
MDA-MB-415
HR+
Luminal
Pemetrexed
TYMS/DHFR/GARFT
TYMS
7511.095
uM
inf
0.05330
0.6055 0.6600 0.5805 0.2746
0.7635
1.1565
MDA-MB-415
HR+
Luminal
PS-1145
IKK
NFKB
7512.065
uM
inf
inf
0.9567 0.9567 0.0000 0.0006
0.1478
0.9176
MDA-MB-415
HR+
Luminal
PS-1145
IKK
NFKB
7511.065
uM
inf
inf
0.9780 0.9780 0.0000 0.0568
0.1924
1.2217
MDA-MB-415
HR+
Luminal
PS-1145
IKK
NFKB
7510.065
uM
inf
inf
0.8713 0.8713 0.0000 0.0068
0.3129
0.6831
MDA-MB-415
HR+
Luminal
Purvalanol A
CDK1
CDK
7511.067
uM
inf
inf
1.0500 1.0500 0.0000 -0.0461
-21.9241
1.1247
MDA-MB-415
HR+
Luminal
Purvalanol A
CDK1
CDK
7512.067
uM
inf
inf
1.0267 1.0267 0.0000 -0.0348
-1.5841
0.8735
MDA-MB-415
HR+
Luminal
Purvalanol A
CDK1
CDK
7510.067
uM
170.140
174.92770
0.5243 -0.0744 5.0000 0.0185
0.8706
0.8348
MDA-MB-415
HR+
Luminal
Ribavirin
15325.211
uM
111.08590
59.48180
0.6204 0.1914 0.7727 0.0371
0.8888
1.1289
MDA-MB-415
HR+
Luminal
SB-3CT
MMP2/9
MMP
10938.144
uM
inf
inf
0.4637 0.4637 0.0000 0.2410
0.4109
1.1369
MDA-MB-415
HR+
Luminal
SB-3CT
MMP2/9
MMP
12333.168
uM
10.84550
18.51560
-0.9988 -1.0000 2.0540 0.3650
0.9888
0.5815
MDA-MB-415
HR+
Luminal
Selumetinib
MEK
MAPK
12333.155
uM
1.8070
19.85380
-0.2260 -1.0000 0.4584 0.3220
0.9946
0.5790
MDA-MB-415
HR+
Luminal
Selumetinib
MEK
MAPK
10938.155
uM
inf
inf
1.0500 1.0500 0.0000 -0.0500
-inf
0.5336
MDA-MB-415
HR+
Luminal
Sigma A6730
AKT
AKT
12333.165
uM
0.17777
1.04950
-0.9950 -1.0000 0.6187 0.7648
0.9148
0.6207
MDA-MB-415
HR+
Luminal
Sigma A6730
AKT
AKT
10938.153
uM
8.03970
10.01450
-0.9996 -0.9994 5.0000 0.3668
0.9294
0.4228
MDA-MB-415
HR+
Luminal
Sirolimus
MTOR
MTOR
7510.068
uM
0.00143
0.00123
0.0726 0.0555 0.7570 0.8274
0.9007
0.7539
MDA-MB-415
HR+
Luminal
Sirolimus
MTOR
MTOR
7512.069
uM
0.00214
0.00191
-0.1700 0.0447 0.8144 0.7014
0.9143
0.8684
MDA-MB-415
HR+
Luminal
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7511.084
uM
105.12280
70.09760
0.0906 0.4331 4.9649 0.1391
0.6533
1.1467
MDA-MB-415
HR+
Luminal
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7510.084
uM
13.99840
635.2080
-0.2676 -1.0000 0.2880 0.3960
0.6651
0.8702
MDA-MB-415
HR+
Luminal
Sorafenib
PDGFR/VEGFR/KIT/FLT3
RTK
7512.084
uM
531.91040
609.73640
-0.1657 -0.3420 3.8168 0.0476
0.9879
0.7511
MDA-MB-415
HR+
Luminal
Sunitinib
PDGFR/VEGFR/KIT/FLT3
RTK
7511.067
uM
inf
inf
-0.9799 -0.9799 0.0000 0.3057
0.4468
1.1247
MDA-MB-415
HR+
Luminal
Sunitinib
PDGFR/VEGFR/KIT/FLT3
RTK
7510.067
uM
4.98990
6.21590
-0.9998 -0.9998 5.0000 0.5373
0.9931
0.8348